Bloomberg the Company

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Bloomberg News

P&G Wins EU Approval for Teva Over-the-Counter Drug Venture

November 12, 2012

Procter & Gamble Co. (PG:US), the world’s largest consumer-products maker, and Teva Pharmaceutical Industries Ltd. won European Union approval for a joint venture to sell over-the-counter medicines.

The European Commission said the deal didn’t raise competition concerns because the combined market share for pain killers and cough medicine would remain relatively low and P&G would continue to face rivalry. It said it approved the deal as P&G’s proposed acquisition of Teva’s over-the-counter business.

Paul Williams, a spokesman for Teva, said P&G will have a 51 percent stake in the venture, PGT Healthcare, and Teva will hold the remainder.

“This is a joint initiative that has ongoing involvement from the two parties,” Williams said in by e-mail.

To contact the reporter on this story: Aoife White in Brussels at

To contact the editor responsible for this story: Anthony Aarons at

The Aging of Abercrombie & Fitch
blog comments powered by Disqus